FDA says it will move against the ingredient supply behind mass-marketed compounded GLP-1s

The Food and Drug Administration announced on 6 February that it intends to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs — the raw material rather than the finished product [s1].

The statement, issued under the name of Commissioner Martin A. Makary, names Hims & Hers and "other compounding pharmacies" as companies mass-marketing such products as similar alternatives to FDA-approved drugs [s1]. The stated rationale is that FDA cannot verify the quality, safety or efficacy of these drugs [s1].

What the agency said it will do

Two lines of action are described.

The first is the API restriction: decisive steps to restrict GLP-1 active pharmaceutical ingredients intended for use in non-approved compounded drugs being mass-marketed as similar alternatives to approved products [s1].

The second concerns advertising. FDA says it is taking steps to combat misleading direct-to-consumer advertising and marketing, following warning letters sent in the fall of 2025 [s1]. The agency sets out three specific claims that may not be made in promotional materials for non-approved compounded products [s1]:

• that they are generic versions of, or the same as, drugs approved by FDA;
• that compounded drugs use the same active ingredient as the FDA-approved drugs;
• that compounded drugs are clinically proven to produce results for the patient.

The enforcement language is unusually explicit. Entities engaged in the manufacture, distribution or marketing of unapproved compounded GLP-1 products "should be aware that failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction" [s1].

Why the ingredient, not the pharmacy

Targeting API supply is a different move from inspecting or warning individual compounders, and it is worth being precise about why.

Compounding operates through a network: bulk substance manufacturers, often overseas, supply pharmacies and outsourcing facilities, which formulate finished preparations, which are then prescribed through telehealth platforms. Enforcement against the last stage is retail — it addresses one seller at a time. Enforcement at the ingredient stage addresses the input the whole network depends on.

FDA does not, in this statement, describe the specific legal mechanism it will use, the timeline, or which ingredients or suppliers are covered. It announces intent and cites its authorities under the Federal Food, Drug, and Cosmetic Act generally [s1]. Those details are what determine the practical effect, and they are not in the document.

What is being asserted, and what is not

The safety claim in the statement is a claim about verification, not about observed harm. FDA says these are drugs "for which the FDA cannot verify quality, safety, or efficacy" [s1]. That is a statement about the absence of the approval process, not a report of adverse events attributable to compounded GLP-1 products. The statement contains no adverse event data, no counts, and no specific product findings.

That distinction matters for readers trying to assess personal risk. An unapproved compounded product has not been shown to be unsafe by this announcement; it has been characterised as unverifiable. Those are different epistemic positions, and only the second is what FDA asserts here.

Equally, the three prohibited claims are marketing restrictions. Prohibiting the statement that a compounded product uses "the same active ingredient" as an approved drug is a rule about what may be said, and does not by itself establish what is in any given preparation.

The context this lands in

FDA's related links point to the policy history: the agency's concerns with unapproved GLP-1 drugs used for weight loss, the rules on compounding when drugs are on FDA's drug shortages list, and its earlier clarification of policies for compounders as national GLP-1 supply began to stabilise [s1].

That sequence is the frame. Compounding of drugs that are otherwise commercially available is constrained by law, with shortage status as one of the conditions that opens the door. As shortages resolved, the legal footing for large-scale compounding narrowed. This statement extends enforcement attention from the finished preparations to the ingredient stream feeding them.

What to watch

Whether the restriction arrives as an import alert, a bulk substances listing decision, or some other instrument. Each has a different scope and a different speed.

Whether named companies contest the action, and on what grounds. The statement's reference to seizure and injunction indicates FDA anticipates the possibility of litigation.

And what happens to people currently taking compounded products if supply contracts quickly. The statement does not address continuity of care, and FDA is not the agency that manages it.

This is informational reporting on a regulatory announcement, not guidance. Decisions about any prescribed or compounded medicine belong with a treating clinician.

Sources

• [s1] U.S. Food and Drug Administration, "FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs," statement from Commissioner Martin A. Makary, 6 February 2026. https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs